Total Payments
$3,118
2024 Payments
$1,241
Companies
16
Transactions
94
Medicare Patients
3,185
Medicare Billing
$280,141
Payment Breakdown by Category
Food & Beverage$2,949 (94.6%)
Education$168.98 (5.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,949 | 92 | 94.6% |
| Education | $168.98 | 2 | 5.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $918.21 | 27 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $368.89 | 5 | $0 (2024) |
| Nevro Corp. | $317.91 | 5 | $0 (2023) |
| Incyte Corporation | $220.00 | 9 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $204.56 | 7 | $0 (2023) |
| Janssen Biotech, Inc. | $178.84 | 9 | $0 (2024) |
| GENZYME CORPORATION | $160.15 | 5 | $0 (2024) |
| Lilly USA, LLC | $150.46 | 3 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $140.19 | 5 | $0 (2024) |
| ABBVIE INC. | $139.15 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,241 | 37 | Amgen Inc. ($713.77) |
| 2023 | $634.37 | 19 | E.R. Squibb & Sons, L.L.C. ($237.53) |
| 2022 | $498.85 | 20 | Incyte Corporation ($122.00) |
| 2021 | $743.69 | 18 | Nevro Corp. ($271.15) |
All Payment Transactions
94 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $15.40 | General |
| Category: Dermatology | ||||||
| 11/22/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: Inflammation | ||||||
| 11/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $45.10 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $33.63 | General |
| Category: Inflammation | ||||||
| 11/11/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: DERMATOLOGY | ||||||
| 11/08/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $28.98 | General |
| Category: Inflammation | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $131.36 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $19.82 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: DERMATOLOGY | ||||||
| 10/31/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $10.36 | General |
| Category: Inflammation | ||||||
| 10/23/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $9.52 | General |
| Category: Inflammation | ||||||
| 10/10/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Inflammation | ||||||
| 10/02/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Inflammation | ||||||
| 09/24/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $16.07 | General |
| 09/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Immunology | ||||||
| 09/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $29.98 | General |
| Category: IMMUNOLOGY | ||||||
| 08/21/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: DERMATOLOGY | ||||||
| 08/21/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: DERMATOLOGY | ||||||
| 08/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.85 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/15/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Inflammation | ||||||
| 08/07/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $121.13 | General |
| Category: Inflammation | ||||||
| 08/02/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Inflammation | ||||||
| 07/23/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $5.68 | General |
| Category: Inflammation | ||||||
| 06/13/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 701 | 1,322 | $293,458 | $68,434 |
| 2022 | 15 | 752 | 1,349 | $259,049 | $55,430 |
| 2021 | 15 | 526 | 955 | $214,008 | $48,803 |
| 2020 | 19 | 1,206 | 2,147 | $374,385 | $107,474 |
Total Patients
3,185
Total Services
5,773
Medicare Billing
$280,141
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 118 | 174 | $41,934 | $10,086 | 24.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 47 | 73 | $34,675 | $8,793 | 25.4% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 15 | 26 | $25,610 | $7,975 | 31.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 80 | 100 | $32,500 | $7,290 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 45 | 74 | $25,234 | $6,098 | 24.2% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 15 | 25 | $20,375 | $5,185 | 25.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 63 | 63 | $18,963 | $4,244 | 22.4% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 35 | 57 | $19,950 | $3,984 | 20.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 89 | 116 | $22,040 | $3,535 | 16.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 46 | 52 | $15,080 | $2,944 | 19.5% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 18 | 27 | $10,125 | $2,500 | 24.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 78 | 474 | $9,480 | $2,350 | 24.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $7,512 | $1,538 | 20.5% |
| 11300 | Shaving of skin growth of body, arms, or legs, 0.5 cm or less | Office | 2023 | 16 | 24 | $6,960 | $1,135 | 16.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 20 | $3,020 | $777.51 | 25.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 155 | 218 | $53,343 | $12,065 | 22.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 91 | 91 | $27,490 | $6,092 | 22.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 36 | 51 | $24,126 | $5,675 | 23.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 61 | 78 | $24,818 | $5,265 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 56 | $19,233 | $4,363 | 22.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 60 | 69 | $19,975 | $4,000 | 20.0% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2022 | 39 | 63 | $21,442 | $3,713 | 17.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 85 | 106 | $19,609 | $3,399 | 17.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $11,185 | $2,488 | 22.2% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2022 | 25 | 31 | $11,408 | $2,427 | 21.3% |
About Michael Hoosier, PA-C
Michael Hoosier, PA-C is a Medical healthcare provider based in Bakersfield, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2016. The National Provider Identifier (NPI) number assigned to this provider is 1952850604.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Hoosier, PA-C has received a total of $3,118 in payments from pharmaceutical and medical device companies, with $1,241 received in 2024. These payments were reported across 94 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($2,949).
As a Medicare-enrolled provider, Hoosier has provided services to 3,185 Medicare beneficiaries, totaling 5,773 services with total Medicare billing of $280,141. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical
- Location Bakersfield, CA
- Active Since 09/22/2016
- Last Updated 02/19/2017
- Taxonomy Code 363AM0700X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1952850604
Products in Payments
- Otezla (Drug) $918.21
- DUPIXENT (Biological) $300.34
- Sotyktu (Drug) $299.90
- Omnia (Device) $175.54
- REMICADE (Biological) $140.86
- OPZELURA (Drug) $120.01
- TREMFYA (Drug) $106.60
- Senza II (Device) $95.61
- VTAMA (Drug) $83.40
- COSENTYX (Drug) $60.18
- EUCRISA (Drug) $59.74
- SKYRIZI (Biological) $57.25
- Ilumya (Biological) $56.37
- Winlevi (Drug) $54.68
- TALTZ (Drug) $50.36
- ILUMYA (Biological) $47.47
- Senza (Device) $46.76
- BLU-U (Medical Supply) $46.04
- AMELUZ (Drug) $31.14
- HUMIRA (Biological) $22.89
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Doctors in Bakersfield
Mr. Geo Mathew, Pa-C, PA-C
Medical — Payments: $15,244
Medical $15,244
Andres Ordonez, Pa, PA
Medical — Payments: $11,883
Medical $11,883
Vicente Benavidez, Pa-C, PA-C
Medical — Payments: $10,895
Medical $10,895
Janice Knowlton, Pa, PA
Medical — Payments: $9,058
Medical $9,058
Robin Reyes, Pa-C, PA-C
Medical — Payments: $2,821
Medical $2,821
Mr. Carlos Flores, Pa, PA
Medical — Payments: $2,099
Medical $2,099